[태그:] 영문
-

Try GEBRA: A Hands-On Variant Interpretation Experience
If you have been curious about GEBRA but did not want to start with a demo request, there is now an easier way to explore the platform. The new GEBRA tutorial experience is now live. You can walk through the actual GEBRA interface and see how the variant interpretation workflow progresses step by step—without scheduling…
-

3billion to Showcase Newborn Genomic Screening Service ‘3B-NEO’ at SSIEM 2026
SEOUL, South Korea, August 24, 2026 — 3billion, an AI-powered rare disease diagnostics company, announced that it will participate in SSIEM 2026, taking place August 25–28 in Helsinki, Finland. At the symposium, 3billion will showcase its whole-exome sequencing (WES)-based rare disease diagnostic service and 3B-NEO, its genomic newborn screening (gNBS) service. The company aims to…
-

Episode 13: CADASIL vs. CARASIL: What Differs in Genetic Interpretation?
When recurrent stroke and extensive white matter changes are observed together with findings that suggest a genetic cause — such as a family history or relatively early onset — hereditary cerebral small vessel disease (CSVD) should be considered. CADASIL and CARASIL are the representative conditions in this group. The two conditions are clinically quite similar,…
-
![[Baby Care #10] How Newborn Screening Programs Differ By Country](http://d15q5w6b9vqac5.cloudfront.net/wp-content/uploads/2026/08/19223952/caring-young-mother-kissing-babys-feet-close-up-scaled.jpg)
[Baby Care #10] How Newborn Screening Programs Differ By Country
Newborn screening (NBS) programs differ significantly from one country to another. The number of conditions screened for can range from a single disorder to more than 40, depending on national health policies. Variations are driven by differences in evidence requirements, cost-effectiveness analyses, and healthcare system structures. The core goal remains universal: early detection of treatable…
-
![[Interpretation Notes #2] ROH vs. UPD: Similar Genomic Patterns, Different Biological Meanings](http://d15q5w6b9vqac5.cloudfront.net/wp-content/uploads/2026/08/14181214/Gemini_Generated_Image_lrd5zzlrd5zzlrd5-%EB%B3%B5%EC%82%AC.png)
[Interpretation Notes #2] ROH vs. UPD: Similar Genomic Patterns, Different Biological Meanings
Genomic sequencing can reveal long stretches of the genome in which the variants are predominantly homozygous. These regions of homozygosity (ROH) can provide important clues about an individual’s inheritance pattern and may help identify clinically relevant genetic mechanisms. One mechanism that can produce a large ROH is uniparental disomy (UPD). However, an ROH does not…
-

3billion Selected for Philippine Government-Led Newborn Genomic Diagnostics Project
SEOUL, South Korea, June 11, 2026 — 3billion, an AI-powered rare disease diagnostics company, announced that it has been selected to provide genomic diagnostic services for a newborn screening project led by the Institute of Human Genetics (IHG) of the National Institutes of Health at the University of the Philippines Manila. The project will provide…
-

3billion Signs Genomic Analysis Contract with Asan Medical Center for K-gNBS Project
SEOUL, South Korea, June 15, 2026 — 3billion, an AI-powered rare disease diagnostics company, has signed a contract with Asan Medical Center to provide genomic analysis and variant interpretation for the Whole-Genome Sequencing-Based Newborn Screening (K-gNBS) Project. Supported by the Korea Disease Control and Prevention Agency (KDCA), K-gNBS is a research project focused on genetic…
-

3billion Showcases AI-Powered Genomic Testing Capabilities at ESHG 2026
SEOUL, South Korea, June 16, 2026 — 3billion, an AI-powered rare disease diagnostics company, announced that it showcased its AI-powered genetic testing services at the European Human Genetics Conference (ESHG 2026), held in Gothenburg, Sweden, from June 13 to 16. Organized by the European Society of Human Genetics (ESHG), the European Human Genetics Conference is…
-

3billion to Attend the 2026 BIO International Convention
SEOUL, South Korea, June 18, 2026 — 3billion, an AI-powered rare disease diagnostics company, announced that it will attend the BIO International Convention, taking place in San Diego from June 22 to 25. Hosted by the Biotechnology Innovation Organization (BIO), the convention is the world’s largest and most comprehensive event for the biotechnology industry. It…
-

3billion’s H1 2026 Revenue Rises 56% to KRW 7.2 Billion
SEOUL, South Korea, August 13, 2026 — 3billion, an AI-powered rare disease diagnostics company, reported consolidated revenue of KRW 7.2 billion for the first half of 2026, up 56% from approximately KRW 4.6 billion in the same period last year. Second-quarter revenue reached KRW 3.8 billion, up 46% year over year and 13% quarter over…